Antisense oligonucleotides can effectively modulate (i.e., decrease) the Bcl-xL/Bcl-xS ratio to favor prostate cancer cell sensitization to radiation and chemotherapeutic agents [36]. This evidence concerns the gene BCL2L1 and prostate carcinoma.